A Phase I/II, Open-Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3235 When Administered Orally to Patients With Prostate Cancer.

Trial Profile

A Phase I/II, Open-Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3235 When Administered Orally to Patients With Prostate Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2011

At a glance

  • Drugs HE 3235 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 08 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 28 Feb 2011 Status changed from active, no longer recruiting to completed.
    • 07 Feb 2011 Status changed from recruiting to active, no longer recruiting. According to a Harbor Bioscience media release the clinical trial sites in the USA have been closed. The final patient number was reported and final statistical results will follow.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top